Voclosporin denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for voclosporin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Voclosporin as Experimental

An experimental or investigational denial for voclosporin (Lupkynis) is a denial that warrants close scrutiny, because voclosporin holds FDA approval for the treatment of active lupus nephritis in adults. When an insurer classifies an FDA-approved drug as experimental, it typically means either: (1) the plan's coverage policy has not been updated to reflect the approval, (2) the drug is being used for an off-label indication, or (3) the plan is applying a broader "clinical acceptance" standard that requires evidence beyond FDA approval.

For an on-label use, FDA approval is the primary rebuttal to an experimental denial. The FDA's review process is the federal standard for evaluating safety and efficacy, and approval signifies that the agency has determined the evidence meets that standard.

## Why This Denial Is Appealable

Lupus nephritis is a serious, organ-threatening autoimmune condition. A denial that prevents access to an FDA-approved treatment on experimental grounds is subject to independent medical review, and IROs are required to evaluate clinical evidence using objective, evidence-based standards — not simply defer to the insurer's internal policy. Additionally, major rheumatology and nephrology professional societies have incorporated voclosporin into their treatment guidance, further supporting its medical acceptance.

## Your Federal Appeal Rights

Under ACA §2719, experimental denials are among the categories specifically subject to mandatory external review rights. Under ERISA §503, self-funded employer plans must provide full-and-fair review. The external-review window is generally approximately four months from the denial notice. Given the serious nature of lupus nephritis, expedited review is often clinically warranted — request it explicitly.

## The Appeal Process

1. Obtain the denial and the policy. Request Aetna's written rationale and the specific coverage policy version that defines voclosporin as experimental. 2. Level 1 internal appeal. Lead with the FDA-approved prescribing label. Include the prescriber's letter and relevant guideline organization references. 3. External review. If denied internally, file for IRO review immediately. The IRO will evaluate independently whether the experimental classification is clinically justified.

## Documentation to Gather

• FDA prescribing label: Confirmation of FDA approval for active lupus nephritis in adults, with the approved indication section clearly referenced.
• Diagnosis and disease activity: Kidney biopsy results, rheumatology/nephrology notes, and lab records documenting active lupus nephritis.
• Prescriber medical-necessity letter: Citing FDA approval, the applicable rheumatology/nephrology society guideline organization's position, and the clinical rationale for this patient.
• Prior treatment history: Documentation of earlier immunosuppressive regimens tried, with dates and outcomes, to contextualize the clinical decision.
• Guideline organization support: Reference (without reproducing specific numbers) the relevant professional society's endorsement of voclosporin in lupus nephritis management.

## Criteria-Mapping Structure

Obtain Aetna's coverage policy for voclosporin. For each criterion used to classify a drug as experimental or investigational, match it to a specific piece of evidence: FDA label language, guideline organization statements, and chart-based facts. A direct criterion-by-criterion rebuttal — showing that each element of "medical acceptance" is satisfied — is the most effective structure for this type of appeal.